Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

NutraLife Biosciences, Inc. (NLBS) had Revenue of $0.63M for the most recently reported fiscal year, ending 2021-12-31.

Quarterly Annual

Figures for fiscal year ending 2021-12-31

Income Statement Financials
Revenue	$0.63M
Net Income	$-5.83M
Cost of Goods Sold	$0.54M
Gross Profit	$0.08M
Operating Expenses	$5.10M
Operating Income	$-4.47M
Non-Operating Income/Expense	$-1.35M
Pre-Tax Income	$-5.83M
Normalized Pre-Tax Income	$-5.83M
Income after Taxes	$-5.83M
Income from Continuous Operations	$-5.83M
Consolidated Net Income/Loss	$-5.83M
Normalized Income after Taxes	$-5.83M
EBIT	$-4.47M
EBITDA	$-3.71M
Weighted-Average Shares Outstanding (Basic)	164.53M
Weighted-Average Shares Outstanding (Diluted)	164.53M
Earnings per Share (EPS) (Basic)	$-0.04
Earnings per Share (EPS) (Diluted)	$-0.04
Balance Sheet Financials
Current Assets	$0.52M
Property, Plant, and Equipment	$2.27M
Long-Term Assets	$4.33M
Total Assets	$4.85M
Current Liabilities	$5.20M
Long-Term Debt	$0.01M
Long-Term Liabilities	$0.36M
Total Liabilities	$5.56M
Common Equity	$-0.71M
Tangible Shareholders Equity	$-1.24M
Shareholders Equity	$-0.71M
Common Shares Outstanding	171.40M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-0.49M
Cash Flow from Investing Activities	$-0.68M
Cash Flow from Financial Activities	$1.30M
Beginning Cash	$0.00M
End Cash	$0.14M
Increase/Decrease in Cash	$0.14M
Stock-Based Compensation	$2.57M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.10
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.02
Debt to Equity Ratio	-3.72
Gross Margin	13.34%
Operating Margin	-713.77%
EBIT Margin	-713.77%
EBITDA Margin	-591.75%
Pre-Tax Profit Margin	-929.99%
Profit Margin	-929.99%
Free Cash Flow	$-0.49M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.13
Inventory Turnover	1.76
Receiveable Turnover	14.18
Days Sales in Receivables	25.74
Return on Equity	817.86%
Return on Tangible Equity	470.84%
Return on Assets	-120.13%
Return on Investments	830.82%
Book Value Per Share	$-0.00
Free Cash Flow per Share	$-0.00
Operating Cash Flow per Share	$-0.00

Data from Zacks Investment Research, Inc.